Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03764098 · ClinicalTrials.gov registry record · Phase 2

Mechanistic Evaluation of Guanfacine on Drinking Behavior in Women and Men With Alcohol Use Disorders

A Phase 2 study of Alcohol Use, sponsored by Yale University.

Recruiting
Registry status
Phase 2
Development phase
160
Enrollment target
1
Study location

NCT03764098 is a Phase 2 study of Alcohol Use that is actively recruiting participants, run by Yale University. The registered enrollment target is 160 participants, below the 263-participant average among 23 other Alcohol Use trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03764098, a Phase 2 study of Alcohol Use, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
Phase 2
Development phase
160 participants
Enrollment target
1
Study location

Study Summary

For this protocol, the investigators plan to collect pilot data to examine sex differences in guanfacine's effect on 1) counteracting stress and stimulation based drinking behavior in the laboratory and 2) improving clinical outcomes during a subsequent treatment phase.

Conditions Studied

Interventions

  • OTHER Placebo
  • DRUG Guanfacine ER

Study Locations (1)

Connecticut

  • Yale University School of Medicine - New Haven

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2020-08-10
Est. Completion 2026-08-31
Phase Phase 2

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT03764098

The ClinicalTrials.gov registry entry for NCT03764098 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 263-participant average among 23 other Alcohol Use trials with a reported enrollment target (39% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alcohol Use appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03764098 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT03764098 about?

NCT03764098 is a clinical study titled "Mechanistic Evaluation of Guanfacine on Drinking Behavior in Women and Men With Alcohol Use Disorders". For this protocol, the investigators plan to collect pilot data to examine sex differences in guanfacine's effect on 1) counteracting stress and stimulation based drinking behavior in the laboratory and 2) improving clinical outcomes during a subsequent treatment phase.

What is the current status of trial NCT03764098?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2020-08-10. Estimated completion is 2026-08-31.

What conditions does trial NCT03764098 study?

This clinical trial studies the following conditions: Alcohol Use.

What interventions are being tested in trial NCT03764098?

The interventions under investigation include: Placebo (OTHER), Guanfacine ER (DRUG).

Who is sponsoring clinical trial NCT03764098?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03764098 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcohol Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.